Purpose of review-Neuromuscular diseases are clinically and genetically heterogeneous and probably contains the greatest proportion of causative Mendelian defects than any other group of conditions. These disorders affect muscle and/or nerves with neonatal, childhood or adulthood onset, with significant disability and early mortality. Along with heterogeneity, unidentified and often very large genes, require complementary and comprehensive methods in routine molecular diagnosis. Inevitably this leads to increased diagnostic delays and challenges in the interpretation of genetic variants.
Introduction
Neuromuscular disorders (NMD) are a broad group of conditions that affect muscles (myopathies, dystrophies, ion channel diseases and malignant hyperthermia) (1-6), nerves (Charcot Marie Tooth (CMT) (7, 8), motor neurone disease (MND) (9-13) hereditary spastic paraplegia (14-18) and spinal muscular atrophies (19) (20) (21) and neuromuscular junctions (myasthenic syndromes) (22) . Muscle weakness, wasting, fasciculation, cramps, numbness, respiratory and cranial nerve palsies are common features in several NMDs. These disorders are frequently inherited and extremely heterogeneous with more than 500 implicated genes. There are many subgroups but individually they are rare and often severe, affecting a wide age group from children to adults (23) (24) (25) (26) (27) (28) .
The advance in gene discovery can be attributed to progress in technology development and affordability of next-generation sequencing (NGS); moving from PCR in the 1980s to exome (protein-coding sequences) and gene panels in 2009/10 to the emerging use of genome sequencing in 2015 (29) (Figure 1A and Table 1 and 2). With size and coverage come difficulties with bioinformatics and variant interpretation ( Figure 1B ). Given the extreme heterogeneity of NMDs and the large number of disease genes, they are well suited for the use of NGS (23) . Here we also discuss the challenges of NGS and how the introduction of NGS into research and diagnostic clinical practice has changed the management of NMD patients (Table 1) .
Research and Diagnostic Challenges of NGS
NMD genetic heterogeneity is present in the group as a whole, as well as sub-groups. For example in autosomal recessive limb girdle muscular dystrophy there are over 20 genes implicated and few diagnostic clues to narrow the genetic causes down. The aim of genetic testing is to make a molecular diagnosis but genetic analysis alone is not sufficient to prove a particular genetic variant, the skill of the referring clinician is essential in assessing variants with the clinical differential diagnosis. A diagnosis of an inherited NMD may seem clear in the context of a positive family history or when multiple siblings are affected but the mode of inheritance is often difficult to define in small families or where family history may be lacking, as in apparently 'sporadic' cases where the mode of inheritance can be any pattern or de-novo dominant. The lack of family history and indistinct NMD phenotypes makes filtering of NGS data difficult, often requiring other unaffected family members to help with genetic proof and the need for further functional laboratory work as proof (30, 31) .
In the pre-NGS era, we and others have published screening and guidelines for genetic testing of NMD such as CMT (7) that were based on careful phenotyping and sequential Sanger sequencing of the most prevalent candidate genes. Although achieving a genetic diagnosis in over 60% of patients with CMT, Sanger sequencing of the ever increasing number of individual genes is no longer cost or time effective. In CMT type 1, over 70% of patients have the 17p duplication and over 80% of patients receive a diagnosis using traditional methods but in CMT2, distal HMN and HSN, where 40-80% of disease-causing genes are unknown the diagnostic rates are only between 17 and 30% (8). With the advancement in gene discovery and NGS, we would expect these figures to be over 90% when all known and novel genetic causes could be analysed (32) . exons, the titin gene (TTN) (MIM#188840) with 363 exons and an open reading frame spanning over 100 Kb and nebulin gene (NEB) (MIM #161650) with 183 exons may be defective. Different types of defects are detected in NMD genes (23) . For example, 60% of patients with Duchenne and Becker muscular dystrophies have deletions in DMD, 10% have duplications, and the rest have point mutations or small insertions-deletions. Prior to NGS, Sanger sequencing, multiple ligation probe analysis (MLPA) and cytogenetic genomic hybridization (CGH) arrays would often be used to target mutation or deletion hot spots and therefore using unbiased NGS we will likely increase the frequency of detection of defects in these large genes. Although genome sequencing is capable of identifying deletions and duplications, the frequency of these defects in Duchenne and Becker muscular dystrophies may mean that MLPA/CGH array is an easier and more cost effective approach.
Next Generation sequencing
There are a number of challenges in moving from simple Sanger sequencing to the NGS analysis of multiple and eventually all the genes in the genome, aimed at revealing the vast majority of genetic variants. The advent of NGS has in the last decade led to an era of inexpensive, high-throughput DNA sequencing of large numbers of genes in a single reaction, thus facilitating the discovery of novel disease genes and variants (6, 10, 33-35).
Whole exome sequencing (WES)
Whole exome sequencing (WES) is an efficient technology that can increase the diagnostic yield when searching for alleles causing rare Mendelian disorders (36) (37) . Exome analyses the protein's encoding region where an estimated 85% of disease-causing mutations are believed to occur. Exomes are enriched by targeted hybridization and then each enriched genomic library is sequenced on a platform such as the Illumina Genome Analyzer II. This procedure covers around 96% of the targeted, mappable bases comprising the exomes of affected individuals. Filtering using databases such as dbSNP (http://www.ncbi.nlm.nih.gov/ SNP/) and 1000 genomes http://www.1000genomes.org/ removes common variants, aiding in identifying the causal gene (Figures 2 and 3) . It has been an invaluable tool in gene discovery, with around 100 genes linked with neuromuscular disorders discovered in this way (38) such as the identification of ADCK3 mutations using exome sequencing as shown in Figure 3 and 5. However, less-reachable regions of the genome with low sequence complexity restrict the ability to design useful WES capture baits, and differences in the hybridization efficiency of WES capture probes can result in off target capture effects as well as regions of the genome such as in exon 1, or GC-rich regions, with little or no coverage (33, 37, (39) (40) (41) .
Gene panels
Gene panels use next-generation sequencing to target genes and regions thought to be relevant to various diseases. Both custom-made panels that can include several hundred genes of interest and off-the-shelf panels of over 6000 genes are available. A custom-made panel with around 160 genes is used by the Diagnostics lab at the Institute of Neurology, and the same panel can be reduced to 40 genes when investigating neuropathies as well as when detecting mitochondrial deletions ( Figure 4 ). Off-the-shelf panels such as Agilent focused exome and the Illumina Trusight panels offer larger-scale screening of genes that are thought important such as all those on the Online Mendelian Inheritance in Man (OMIM) database. They rely on solution hybridization, in which pools of biotinylated oligonucleotide probes, each targeting a segment of the desired capture region, are used to pull down particular pieces of the genome. Gene panels are a quick relatively low-cost screening method to look for a few gene variants associated with specific NMDs.
NGS technologies have also advanced the genetic diagnosis of mitochondrial disorders in sequencing the mitochondrial genome or nuclear genes (42) . A two-step strategy based on a targeted custom-made mitochondrial gene panel with 132 genes, and WES, was used by Legati et al. in a cohort of 125 early onset mitochondrial cases. However, an uncontroversial genetic diagnosis was only possible in 19 patients by targeted gene panel sequencing and in 6 out of 10 by WES. The rest of the cases although initially classified as mitochondriadisease patients, might be carriers of non-mitochondrial gene mutations (34) .
Targeted NGS can be beneficial for diagnosing patients with early presentation of NMDs. Chae et al. used targeted NGS to screen 43 patients presented with early onset neuromuscular disorders of an unknown genetic origin. They were tested by panel for 579 nuclear genes associated with myopathy. Sanger sequencing has been the basic tool used for detecting mutations in myopathies but this is a laborious and expensive technique to be used for large genes. Compared to exome sequencing which is often more costly, has a higher false positive rate and turnaround time, and can be more difficult to interpret, targeted NGS is an attractive solution. Chae et al. were able to diagnose 21 of the 43 patients with a definite genetic cause for myopathy (23) . In a similar way, Evila et al. used a custom-made panel, MyoCap, with 180 myopathy related genes, and succeeded in diagnosing 21 out of 61 patients, with 9 of them having potential disease-causing mutations in TTN (3).
Whole genome sequencing (WGS)
Whole genome sequencing (WGS) allows examination of single-nucleotide variants (SNVs), indels, structural variants (SVs) and copy number variants (CNVs) in both the ~1% part of the genome that encodes protein sequences and the ~99% of remaining non-coding sequences. Therefore, WGS has more reliable sequence coverage with more uniformity. With the start of the 100,000 Project by the NHS in 2012, UCL has become a Genomics Medical Centre where patients with rare, life threatening and debilitating diseases such as many NMDs will be sequenced. Genomics England Clinical Interpretation Partnership (GeCIP) has also been established and aims to enhance clinical interpretation and validation of whole genome sequencing data delivered by the 100,000 genomes project (figure 6). It is likely to reveal many new variants and genes and derive new scientific and clinical findings. With the rapid drop in sequencing cost and the ability of WGS to rapidly produce large volumes of data, it is becoming a powerful tool for genomic research. However, WGS has still not been introduced in daily routine diagnostics, as it still remains more expensive and is more computationally demanding. Both WES and WGS generate vast amounts of complex data depicting the genetic variants, which require intensive filtering and complex interpretation ( 
False positives
Another drawback is the high error rates in NGS compared to Sanger sequencing. Artificial mutations can be produced during template amplification or sequencing, leading to false positive results. Thus, Sanger sequencing of interesting variants detected by NGS is essential in validation but increases cost and turn-around time. This issue can be addressed by improving capture and sequencing approaches to increase variant coverage, achieving more reliable data. In addition, better data filtering protocols can reduce the pool of false positives (43) .
Volume of data
NGS generates a high volume of data which becomes problematic for analysis and storage.
Cloud computing can be a solution for reducing the cost of expensive computing infrastructure but needs to be secure. Importantly, decreasing costs in NGS has outpaced the increase in calculation power and storage capacity of computers. As sequencing becomes cheaper than data storage of the corresponding sequence output, re-sequencing of a patient DNA might be more cost-effective than saving original data (48) .
Variants filtering and mutation identification
Large numbers of variants are detected in NGS, it is difficult to distinguish between individual, rare and non-pathogenic variations without clinical significance versus diseasecausing mutations. Defining the complete list of polymorphisms in different populations will require sequencing of world population groups. A recent study hypothesised that 27 % of published mutations appear to be sequencing errors, common polymorphisms, or have a lack of evidence of pathogenicity (45) . This issue can be addressed by further analysis and validation such as in-silico prediction, detection of mutations in the same gene in unrelated individuals with the same disorder, absence in a control population, co-segregation in affected families and functional studies. Multiple criteria should be combined in order to prove the pathogenicity of the variation. In addition incidental findings can be problematic, especially for unreported diseases. Guidelines should be established and implemented by national committees, as in the case of the Genomics England sequencing project in order to determine whether the analysis and reports should be selective or complete (30) .
Benefits of definitive molecular diagnosis
Identification of disease-causing mutations is vital for patients and families to provide an accurate diagnosis. The knowledge of the mutation and mutated gene improves disease management, and allows for inclusion into therapeutic trials. Genetic counseling is then possible, as carrier status determination and prenatal diagnosis can decrease the risk of recurrence (49) . In addition, finding the disease-causing mutation permits potential phenotype-genotype correlations and greater understanding of the pathophysiological mechanisms, disease pathways and development of potential therapies (50, 51) .
Conclusion
There are limitations and challenges in using NGS but this technology is significantly developed for research and routine diagnostic practice. As the cost of NGS declines and the technology improves leading to obtaining faster and more accurate data, it is strongly anticipated that this recent technology will complement many clinical and pathological investigations to enable diagnosis as well as the identification of disease modifying and pharmacogenomics factors. 
KEY POINTS
• Neuromuscular disorders are clinically heterogeneous. There is a broad spectrum of disease ranging from myopathy and CMT through to the more aggressive neuromuscular impairment in MND.
• Next-generation sequencing technologies have helped greatly in diagnosing these disorders and underpinning the genetic pathways.
• Technology has evolved to create large disease gene panels through to whole exome sequencing, and final transition to whole genome sequencing.
• The understanding of genetic causes and disease pathways in the remainder of neuromuscular disorders will be key to identifying treatments.
• The formation of collaborative groups such as the neurology and neuromuscular GeCIP will greatly advance the interpretation and functional understanding of whole genome sequencing. Schematic representation comparing the ease of analysis compared to the amount of genomic data generated per run. In the top panel, the patient has part of the gene deleted (indicated by a circle) which is determined by the greatly reduced coverage depth of that region (red). The bottom panel shows a healthy control patient which has a uniform coverage depth throughout exon 7 of PRX gene. 
